Tumor News and Research

RSS

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Dendreon Corporation announced today the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer. The manuscript is published in the July 29, 2010 issue of the journal.

29 Jul 2010

Champions Biotechnology fiscal 2010 operating revenues increase to $4.89 million

Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced its financial results for the fiscal year ended April 30, 2010.

29 Jul 2010

Etubics enters Phase I trials for next generation vector vaccines

Etubics Corporation, a biopharmaceutical company developing next generation vector vaccines, has entered into Phase I trials at Duke University with its ETBX-011, a therapeutic vaccine candidate that is intended to treat Carcinoembryonic Antigen expressing cancers such as colorectal cancer. Etubics dosed its first patient yesterday. Etubics was recently granted clearance by the U.S. Food and Drug Administration for its Investigational New Drug application to begin studying ETBX-011 in humans.

29 Jul 2010

Kyowa Hakko Kirin initiates Phase 2 trial of ARQ 197 for gastric cancer: ArQule

ArQule, Inc. today announced the initiation of a Phase 2, single agent trial with ARQ 197 in gastric cancer by Kyowa Hakko Kirin, its exclusive licensee for the development and commercialization of ARQ 197 in the Asian territory consisting of Japan, China (including Hong Kong), South Korea and Taiwan. Initiation of this trial will trigger a $5 million milestone payment to ArQule from Kyowa Hakko Kirin.

28 Jul 2010

Researchers establish new criteria for liver transplantation

Researchers at the University of California, San Francisco propose that treatments used on liver cancers beyond the established Milan criteria for liver transplantation may be appropriate for all patients with hepatocellular carcinoma who are listed for transplantation. Full details appear in the August issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

28 Jul 2010

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos Therapeutics, Inc. today announced topline results from the Company's randomized Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) who had received one or two prior systemic treatments including at least one prior platinum-based regimen. The objective of the trial was to estimate the efficacy of FOLOTYN compared to that of erlotinib as assessed by overall survival.

28 Jul 2010

CPRIT awards UH $2.4 million for new multidisciplinary research

The University of Houston (UH) received a $2.4 million grant to fund the most promising young cancer researchers who are working at the cutting-edge of a new multidisciplinary approach to fighting cancer.The award is part of the latest round of grant disbursements from the Cancer Prevention and Research Institute of Texas (CPRIT), which oversees the state's new billion-dollar war on cancer. It is UH's second CPRIT grant, and the first in the science and engineering fields.

28 Jul 2010

Scientists unveil nanoparticle for photoacoustic imaging

Spotting a single cancerous cell that has broken free from a tumor and is traveling through the bloodstream to colonize a new organ might seem like finding a needle in a haystack. But a new imaging technique from the University of Washington is a first step toward making this possible.UW researchers have developed a multifunctional nanoparticle that eliminates the background noise, enabling a more precise form of medical imaging - essentially erasing the haystack, so the needle shines through. A successful demonstration with photoacoustic imaging was reported today (July 27) in the journal Nature Communications.

28 Jul 2010

Morphine blocks new blood vessel and tumor growth: Study

Current research suggests that taking morphine can block new blood vessel and tumor growth. The related report by Koodie et al, "Morphine suppresses tumor angiogenesis through a HIF1α/p38MAPK pathway," appears in the August 2010 issue of the American Journal of Pathology.

28 Jul 2010

Scientists identify genetic variants for breast cancer

Women with higher risk scores that consisted of having certain genetic variants most strongly linked to breast cancer had an associated higher risk of breast cancer, with these scores also highly predictive of estrogen receptor-positive disease, according to a study in the July 28 issue of JAMA.

28 Jul 2010

NYU Langone opens vascular-targeted photodynamic therapy trial to men with localized prostate cancer

NYU Langone Medical Center has begun a clinical trial offering vascular-targeted photodynamic therapy to patients with localized prostate cancer. This novel, minimally invasive procedure uses a light-activated drug to deliver light energy waves by way of laser fibers in order to destroy prostate cancer cells.

28 Jul 2010

MabCure's MAbs 94% accurate in identifying ovarian cancer

Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.

28 Jul 2010

Attaching transferrin to nanoparticle surface can kill cancer cells

A normally benign protein found in the human body appears to be able - when paired with nanoparticles - to zero in on and kill certain cancer cells, without having to also load those particles with chemotherapy drugs.The finding could lead to a new strategy for targeted cancer therapies, according to the University of North Carolina at Chapel Hill scientists who made the discovery.

28 Jul 2010

New York Times article highlights potential value of early cancer detection technology

Manhattan Scientifics, Inc. said today that a July 20th New York Times article titled "Prone to Error: Earliest Steps to Find Cancer" highlights the potential value of the early cancer detection technology developed by Senior Scientific, LLC and licensed by Manhattan Scientifics. The story focused on widespread problems associated with incorrect diagnosis of breast cancer, and cited one study in which 90,000 women either did not have the disease or their pathologist made an error that resulted in incorrect treatment.

27 Jul 2010

PIK3CA, KRAS mutations in tumor can predict patients’ response to treatment: Research

Drugs such as everolimus that target the protein mTOR are used to treat several forms of cancer, but not all patients respond to the treatment. A team of researchers, led by Alberto Bardelli, at the University of Turin Medical School, Italy, has now identified a way to help predict which patients will respond to such drugs.

27 Jul 2010

Brainlab launches ExacTrac Infrared Monitoring device for patient positioning during radiation therapy

Brainlab announced the availability of ExacTrac® Infrared Monitoring, an add-on device to existing treatment machines for monitoring patient positioning during radiation therapy treatments, at the American Association of Physicists in Medicine (AAPM) Annual Meeting last week.

26 Jul 2010

FDA grants Biovest's BiovaxID vaccine Orphan Drug Designation for mantle cell lymphoma

Biovest International, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID®, Biovest's personalized cancer vaccine, for a second lymphoma indication: mantle cell lymphoma. Mantle cell lymphoma is an aggressive and lethal B-cell blood cancer for which there is no current consensus standard-of-care.

26 Jul 2010

Glioblastomas patients with affected stem cell niche experience progression-free survival

Patients with deadly glioblastomas who received high doses of radiation that hit a portion of the brain that harbors neural stem cells had double the progression-free survival time as patients who had lower doses or no radiation targeting the area, a study from the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center has found.

26 Jul 2010

Scientists develop nanoprobe to detect blood vessel growth in tumors

Formation of new blood vessels, also known as angiogenesis, is crucial for sustained tumor growth and cancer metastasis. Recently, clinically available therapies to suppress the growth of these vessels have been available to improve patient survival in some cancer types. Accurate detection and quantification of blood vessel growth using nonsurgical methods would greatly complement current therapies and allow physicians to quickly assess treatment regimens and adjust them as necessary. In the work published in the August issue of Experimental Biology and Medicine, Kessinger and coworkers have incorporated nanotechnology, material science, and the clinical imaging modality MRI, to create a nanosized probe capable of noninvasively visualizing and quantifying the blood vessel growth in tumors in a preclinical model.

26 Jul 2010

Control of cell migration gene can reduce spread of oral cancer cells: Study

The spread of cancer cells in the tongue may be reduced if a gene that regulates cancer cell migration can be controlled, according to new research at the University of Illinois at Chicago.

26 Jul 2010

Tumor News and Research

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Champions Biotechnology fiscal 2010 operating revenues increase to $4.89 million

Etubics enters Phase I trials for next generation vector vaccines

Kyowa Hakko Kirin initiates Phase 2 trial of ARQ 197 for gastric cancer: ArQule

Researchers establish new criteria for liver transplantation

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

CPRIT awards UH $2.4 million for new multidisciplinary research

Scientists unveil nanoparticle for photoacoustic imaging

Morphine blocks new blood vessel and tumor growth: Study

Scientists identify genetic variants for breast cancer

NYU Langone opens vascular-targeted photodynamic therapy trial to men with localized prostate cancer

MabCure's MAbs 94% accurate in identifying ovarian cancer

Attaching transferrin to nanoparticle surface can kill cancer cells

New York Times article highlights potential value of early cancer detection technology

PIK3CA, KRAS mutations in tumor can predict patients’ response to treatment: Research

Brainlab launches ExacTrac Infrared Monitoring device for patient positioning during radiation therapy

FDA grants Biovest's BiovaxID vaccine Orphan Drug Designation for mantle cell lymphoma

Glioblastomas patients with affected stem cell niche experience progression-free survival

Scientists develop nanoprobe to detect blood vessel growth in tumors

Control of cell migration gene can reduce spread of oral cancer cells: Study

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News